Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: primary endpoint results, effect estimate…
- Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals’ 10-valent Pneumococcal Conjugate Vaccine.: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Na-GST-1 With or Without CpG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02143518).
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04074928).
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity Study of Traveler’s Diarrhea Vaccine Patch: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01067781).
- Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda’s Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore: primary endpoint results, effect estimate with confidence interval,…
- Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance Assessment of a First Four Arms on Demand Open Robotic Solution for Assisted PN, RN and RP: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Assessment of a First Four Arms on Demand Open Robotic Solution for Assisted PN, RN and RP: primary endpoint results, effect estimate with confidence interval,…
- Safety and Performance of ENTACT Septal Staple System for Septoplasty: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of ENTACT Septal Staple System for Septoplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04392583).
- Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of Miami InnFocus Drainage Implant (MIDI Arrow) Glaucoma Drainage Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG): Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Performance Study of the Harpoon Mitral Valve Repair System: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the Harpoon Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Performance Study of the RELIANCE 4-Front Passive Fixation Lead: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the RELIANCE 4-Front Passive Fixation Lead: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma: primary endpoint results, effect…
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del: primary endpoint results, effect estimate with confidence interval, sample-size…
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): primary endpoint results, effect estimate with…